• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A.

作者信息

Shire D, Calandra B, Delpech M, Dumont X, Kaghad M, Le Fur G, Caput D, Ferrara P

机构信息

Sanofi Recherche, Centre de Labège, Labège-Innopole BP 137, 31676 Labège Cédex, France.

出版信息

J Biol Chem. 1996 Mar 22;271(12):6941-6. doi: 10.1074/jbc.271.12.6941.

DOI:10.1074/jbc.271.12.6941
PMID:8636122
Abstract

The antagonist SR 141716A has a high specificity for the central CB1 cannabinoid receptor and negligeable affinity for the peripheral CB2 receptor, making it an excellent tool for probing receptor structure-activity relationships. From binding experiments with mutated CB1 and with chimeric CB1/CB2 receptors we have begun to identify the domains of CB1 implicated in the recognition of SR 141716A. Receptors were transiently expressed in COS-3 cells, and their binding characteristics were studied with SR 141716A and with CP 55,940, an agonist recognized equally well by the two receptors. The region delineated by the fourth and fifth transmembrane helices of CB1 proved to be crucial for high affinity binding of SR 141716A. The CB1 and CB2 second extracellular loops, e2, were exchanged, modifications that had no effect on SR 141716A binding in the CB1 variant but that eliminated CP 55,940 binding in both mutants. The replacement of the conserved cysteine residues in e2 of CB2 by serine also eliminated CP 55,940 binding, but replacement of those in CB1 resulted in the sequestration of the mutated receptors in the cell cytoplasm. The e2 domain thus plays some role in CP 55,940 binding but none in SR 141716A recognition, binding of the latter clearly implicating residues in the adjoining transmembrane helices.

摘要

相似文献

1
Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A.
J Biol Chem. 1996 Mar 22;271(12):6941-6. doi: 10.1074/jbc.271.12.6941.
2
Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528.大麻素受体与拮抗剂SR 141716A和SR 144528的相互作用。
Life Sci. 1999;65(6-7):627-35. doi: 10.1016/s0024-3205(99)00285-4.
3
Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain.[3H]-SR 141716A(一种选择性脑(CB1)大麻素受体拮抗剂)在啮齿动物脑中结合位点的表征与分布
Life Sci. 1996;58(15):1239-47. doi: 10.1016/0024-3205(96)00085-9.
4
Integrity of extracellular loop 1 of the human cannabinoid receptor 1 is critical for high-affinity binding of the ligand CP 55,940 but not SR 141716A.
Biochem Pharmacol. 2003 May 15;65(10):1623-31. doi: 10.1016/s0006-2952(03)00155-2.
5
SR 141716A acts as an inverse agonist to increase neuronal voltage-dependent Ca2+ currents by reversal of tonic CB1 cannabinoid receptor activity.SR 141716A作为反向激动剂,通过逆转CB1大麻素受体的张力性活性来增加神经元电压依赖性Ca2+电流。
Mol Pharmacol. 1998 Dec;54(6):1064-72. doi: 10.1124/mol.54.6.1064.
6
Isolation and expression of a mouse CB1 cannabinoid receptor gene. Comparison of binding properties with those of native CB1 receptors in mouse brain and N18TG2 neuroblastoma cells.
Biochem Pharmacol. 1997 Jan 24;53(2):207-14. doi: 10.1016/s0006-2952(96)00727-7.
7
A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions.一种针对中枢大麻素受体的选择性反向激动剂可抑制胰岛素或胰岛素样生长因子1刺激的丝裂原活化蛋白激酶激活。受体/配体相互作用新模型的证据。
J Biol Chem. 1997 Aug 29;272(35):22330-9. doi: 10.1074/jbc.272.35.22330.
8
Characterization of CB1 receptors on rat neuronal cell cultures: binding and functional studies using the selective receptor antagonist SR 141716A.大鼠神经元细胞培养物中CB1受体的特性:使用选择性受体拮抗剂SR 141716A进行结合和功能研究。
J Neurochem. 1997 Jan;68(1):402-9. doi: 10.1046/j.1471-4159.1997.68010402.x.
9
Dual intracellular signaling pathways mediated by the human cannabinoid CB1 receptor.由人类大麻素CB1受体介导的双重细胞内信号通路。
Eur J Pharmacol. 1999 Jun 25;374(3):445-55. doi: 10.1016/s0014-2999(99)00349-0.
10
Mutational analysis and molecular modelling of the antagonist SR 144528 binding site on the human cannabinoid CB(2) receptor.
Eur J Pharmacol. 2000 Jul 28;401(1):17-25. doi: 10.1016/s0014-2999(00)00439-8.

引用本文的文献

1
Comparison of Agonist Activity between CB1 and CB2 Receptors with Orthosteric Site Mutations.具有正构位点突变的CB1和CB2受体之间激动剂活性的比较。
Receptors (Basel). 2024 Sep;3(3):380-396. doi: 10.3390/receptors3030018. Epub 2024 Aug 6.
2
Recent Advances in Endocannabinoid System Targeting for Improved Specificity: Strategic Approaches to Targeted Drug Delivery.内源性大麻素系统靶向治疗的最新进展:靶向药物递送的策略方法。
Int J Mol Sci. 2022 Oct 30;23(21):13223. doi: 10.3390/ijms232113223.
3
Prospects for new drugs to treat binge-eating disorder: Insights from psychopathology and neuropharmacology.
治疗暴食症新药的前景:精神病理学和神经药理学的见解。
J Psychopharmacol. 2022 Jun;36(6):680-703. doi: 10.1177/02698811211032475. Epub 2021 Jul 28.
4
On the Role of Central Type-1 Cannabinoid Receptor Gene Regulation in Food Intake and Eating Behaviors.中央型 1 型大麻素受体基因调控在摄食和进食行为中的作用。
Int J Mol Sci. 2021 Jan 1;22(1):398. doi: 10.3390/ijms22010398.
5
Neurochemical Markers in the Mammalian Brain: Structure, Roles in Synaptic Communication, and Pharmacological Relevance.哺乳动物大脑中的神经化学标志物:结构、在突触通讯中的作用及药理学相关性。
Curr Med Chem. 2017;24(28):3077-3103. doi: 10.2174/0929867324666170414163506.
6
Chemogenomics knowledgebase and systems pharmacology for hallucinogen target identification-Salvinorin A as a case study.用于致幻剂靶点识别的化学基因组学知识库与系统药理学——以Salvinorin A为例
J Mol Graph Model. 2016 Nov;70:284-295. doi: 10.1016/j.jmgm.2016.08.001. Epub 2016 Aug 8.
7
Minireview: From the bench, toward the clinic: therapeutic opportunities for cannabinoid receptor modulation.小型综述:从实验室到临床:大麻素受体调节的治疗机会
Mol Endocrinol. 2015 Jun;29(6):801-13. doi: 10.1210/me.2015-1062. Epub 2015 Apr 13.
8
Modeling, molecular dynamics simulation, and mutation validation for structure of cannabinoid receptor 2 based on known crystal structures of GPCRs.基于GPCRs已知晶体结构的大麻素受体2结构建模、分子动力学模拟及突变验证
J Chem Inf Model. 2014 Sep 22;54(9):2483-99. doi: 10.1021/ci5002718. Epub 2014 Sep 5.
9
Controlled-deactivation cannabinergic ligands.可控失活大麻素配体。
J Med Chem. 2013 Dec 27;56(24):10142-57. doi: 10.1021/jm4016075. Epub 2013 Dec 10.
10
The membrane proximal region of the cannabinoid receptor CB1 N-terminus can allosterically modulate ligand affinity.大麻素受体 CB1 N 端的膜近端区域可以变构调节配体亲和力。
Biochemistry. 2013 Nov 19;52(46):8286-94. doi: 10.1021/bi400842k. Epub 2013 Nov 8.